Engineered immune cells take aim at stubborn bone cancer
NCT ID NCT05312411
First seen Nov 20, 2025 · Last updated Jun 23, 2026 · Updated 26 times
Summary
This early-phase trial tests a two-part treatment for osteosarcoma that has come back or not responded to standard care. First, a patient's own T cells are collected and genetically modified to become CAR T cells that can recognize a special flag. Then, after some chemotherapy, the CAR T cells are infused back, followed by doses of a molecule (UB-TT170) that attaches to tumor cells and flags them for destruction by the CAR T cells. The study involves 21 participants and focuses on safety and feasibility over about 8 months of active treatment, with long-term follow-up for 15 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
genetically modified CAR T cells (antiFL(FITC-E2)) and a targeting molecule (UB-TT170)
What this could lead to
If it works, this could point toward a new treatment option for osteosarcoma that doesn't respond to standard therapy.
What could go wrong
This is a very early phase 1 trial with only 21 participants, so it's mainly testing safety and feasibility. The treatment may not shrink tumors, and there are risks from chemotherapy and the CAR T cells themselves.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.